Organization
Cystic Fibrosis Canada
- Meetings this Parliament
- 19
- With MPs
- 3
- Since Nov 2021
- 42
- Active registrations
- 1
Most recent reported meeting: Apr 24, 2026.
Lobbying by Cystic Fibrosis Canada: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (organization) In effect since Oct 19, 2026
Filed by Kelly Grover, President and Chief Executive Officer
Lobbyists
- Johanne Ouedraogo · Program lead- healthcare and community relations
- Kelly Grover · CEO
- Kim Steele · Director, Government and Community Relations
- Paul Eckford · Chief Scientific Officer
Institutions they may lobby: Canada Revenue Agency (CRA), Canadian Institutes of Health Research (CIHR), Finance Canada (FIN), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Office of the Auditor General of Canada (OAG), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS)
What they're lobbying on (7)Hide details
- Increased federal investment in health-related research.
- Advocating for implementation of Canada's drugs for rare diseases strategy.
- With respect to disability, we advocate for recognition of and supports for people with episodic disabilities.
- In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
- In terms of research and development, we lobby for support of cystic fibrosis research initiatives that improve the health and wellness of Canadians living with cystic fibrosis.
- Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
- Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
Registration 939590-266824-35. Look it up in the official Registry
Reported meetings
Spreadsheet-
Reported by Kelly Grover · In-house (organization)
- Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB). Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Galen Richardson · Director of Stakeholder Relations, Privy Council Office (PCO)
Advocating for implementation of Canada's drugs for rare diseases strategy. Read more
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Nasser Haidar · Senior Policy Advisor for Canada-U.S. Trade, One Canadian Economy, and Intergovernmental Affairs, Privy Council Office (PCO)
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB). Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Daniel MacDonald · Director General, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases. Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
-
Reported by Kelly Grover · In-house (organization)
- Jocelyn Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Advocating for implementation of Canada's drugs for rare diseases strategy. Read more
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Tom Kmiec · Deputy Speaker
Advocating for implementation of Canada's drugs for rare diseases strategy. Read more
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
-
Reported by Kelly Grover · In-house (organization)
- Kelly Robinson · Director General, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases. Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
-
Reported by Kelly Grover · In-house (organization)
- Bruno Rodrigue · Executive Director, Health Canada (HC)
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB). Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- David Lee · Chief Regulatory Officer, Health Canada (HC)
Advocating for implementation of Canada's drugs for rare diseases strategy. Read more
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Dan Mazier · Member of Parliament
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB). Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Sonia Sidhu · Member of Parliament
- Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases. Read more
Advocating for implementation of Canada's drugs for rare diseases strategy.
Advocating to stop the regulatory changes to the Patented Medicines Price Review Board (PMPRB).
-
Reported by Kelly Grover · In-house (organization)
- Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Daniel MacDonald · Director General, Drugs for Rare Diseases, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding. Read more
-
Reported by Kelly Grover · In-house (organization)
- Rodrigo Arancibia · Acting Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases. Read more
In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
Increased federal investment in health-related research.
-
Reported by Kelly Grover · In-house (organization)
- Supriya Sharma · Chief Medical Advisor to the Deputy Minister and Senior Medical Advisor, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
-
Reported by Kelly Grover · In-house (organization)
- David Lee · Chief Regulatory Officer, Health Canada (HC)
Increased federal investment in health-related research. Read more
Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
-
Reported by Kelly Grover · In-house (organization)
- Mike Morrice · Member of Parliament, House of Commons
Health
-
Reported by Kelly Grover · In-house (organization)
- Eric Duncan · Member of Parliament
Health
-
Reported by Kelly Grover · In-house (organization)
- Adam van Koeverden · Member of Parliament
Health
-
Reported by Kelly Grover · In-house (organization)
- Don Davies · Member of Parliament
Health
-
Reported by Kelly Grover · In-house (organization)
- James Maloney · Member of Parliament
Health
-
Reported by Kelly Grover · In-house (organization)
- Tim Louis · Member of Parliament
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.